Neuralstem Shares Collapse on Clinical Setback Shares of Neuralstem, Inc. (NASDAQ:CUR) were hit hard Tuesday after news that its MDD drug failed a …
Neuralstem, Inc. (NASDAQ: CUR) announced a reverse stock split of its shares of common stock at a ratio of 1-for-13.
Neuralstem, Inc. (NASDAQ:CUR) announces the closing of Tianjin Pharmaceutical Group International Holdings Co.
In a research report released Tuesday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR) with a price …
Neuralstem, Inc. (NASDAQ:CUR) reported its financial results and provided business and clinical updates for the three and nine month periods ended September 30, 2016.
Neuralstem, Inc. (NASDAQ:CUR) announced the presentation of the poster entitled, “Reversal of radiation-induced cognitive impairment by oral administration of a neurogenic small molecule compound …
In a research report released Tuesday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR) with a price target …
Neuralstem, Inc. (NASDAQ:CUR) shares are climbing nearly 6% after announcing this morning it had entered into an official agreement with Tianjin Pharmaceutical Holding Group, …
In a research report released Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR), while slashing the …
In a research report issued Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR), with an $8.
